Future therapeutic strategies in inflammatory cardiomyopathy: insights from the experimental autoimmune myocarditis model.
Inflammatory cardiomyopathy is a common cause of heart failure developing on a basis of cardiac inflammation. Cardiac inflammation - or myocarditis - is usually triggered by infections or cardiac damage of any cause. Experimental autoimmune myocarditis refers to a CD4(+) T cell-mediated mouse model of inflammatory cardiomyopathy. So far, the experimental autoimmune myocarditis model helped us to understand the role of various chemokines, cytokines, and cell subsets in the progression of inflammatory heart disease. Here, we review the current therapeutic options for inflammatory cardiomyopathy, and delineate potential future treatment approaches from the most recent mechanistic insights given by the experimental autoimmune myocarditis model.
Blyszczuk
Przemyslaw
P
Department of Cardiology, University Hospital, Rämistrasse 100, CH-8091 Zurich, Switzerland.
Valaperti
Alan
A
Eriksson
Urs
U
D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D009202:Cardiomyopathies / Q000188:drug therapy* / Q000276:immunology; D018925:Chemokines / Q000378:metabolism; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D018450:Disease Progression; D016503:Drug Delivery Systems; D006801:Humans; D051379:Mice; D009205:Myocarditis / Q000188:drug therapy* / Q000276:immunology
D018925:Chemokines; D016207:Cytokines